Silvio Traversa
Chief Tech/Sci/R&D Officer at SIENNA BIOPHARMACEUTICALS, INC.
Silvio Traversa active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-11-30 | - |
Career history of Silvio Traversa
Former positions of Silvio Traversa
| Companies | Position | Start | End |
|---|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Chief Tech/Sci/R&D Officer | 2007-09-30 | 2016-11-30 |
| Corporate Officer/Principal | 2005-01-31 | 2007-09-30 | |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - | - |
Training of Silvio Traversa
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Statistics
International
| Italy | 4 |
| United States | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
| Industria Farmaceutica Serono SpA |
- Stock Market
- Insiders
- Silvio Traversa
- Experience
